Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. METHODS AND FINDINGS: NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid. CONCLUSIONS: The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease. TRIAL REGISTRATION: Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A phase III trial (NCT02017340) testing the efficacy and safety of nilvadipine (29) in participants with mild to moderate AD indicated that, while the drug demonstrated good safety, it did not show significant benefits in slowing cognitive decline in AD patients.477”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [477]
The cited source says what the claim attributes to it.
In the citing paper
“The dihydropyridine calcium channel blocker nilvadipine with a capacity of lowering Aβ production and increasing clearance Aβ was evaluated for neuroprotective and anti-inflammatory properties (Lawlor et al., 2018).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Lawlor et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 1×
“In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease [12,13].”
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,374
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 1×
“In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease [12,13].”
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Cited by
Items 101–195 of 195
Gender medicine: Towards a gender-specific treatment of neuropsychiatric disorders
Biskup, E. M., Martínková, J., & Ferretti, M. T. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00029-1 · Cited by 15
Dyer, A. H., Murphy, C., Dolphin, H., Morrison, L., Briggs, R., LAWLOR, B. A., Kennelly, S., NILVAD Study Group, Segurado, R., Kennelly, S., et al. (2024) · European Geriatric Medicine · doi:10.1007/s41999-023-00910-x · Cited by 14
“Detailed inclusion and exclusion criteria are published elsewhere [32, 33].”
Self-citationGonçalves, C., Sesterheim, P., Wartchow, K. M., Bobermin, L. D., Leipnitz, G., & Quincozes‐Santos, A. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.905218 · Cited by 14
Tackling Alzheimer’s Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles
Rampa, A., Gobbi, S., Belluti, F., & Bisi, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831140745 · Cited by 11
Dong, Y., & Tang, L. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01153-3 · Cited by 11
“Several CBBs, such as Nilvadipine and Amlodipine, have demonstrated promising results in randomized clinical trials for the treatment of dementia [22, 23].”
Aguzzoli, E., Walbaum, M., Knapp, M. R. J., Castro‐Aldrete, L., Chadha, A. S., & Cyhlarova, E. (2025) · Archives of Public Health · doi:10.1186/s13690-025-01626-z · Cited by 13
“We found only one study examining the effectiveness of anti-dementia drugs that provided disaggregated data by sex [51].”
Back pain and heart failure in community-dwelling older adults: Findings from the Health ABC study
Chen, J., Zhang, Y., Simonsick, E. M., Starkweather, A. R., Chen, M., McCauley, P., Chyun, D. A., & Cong, X. S. (2021) · Geriatric Nursing · doi:10.1016/j.gerinurse.2021.03.016 · Cited by 13
Shaw, K., Bell, L., Boyd, K., Grijseels, D. M., Clarke, D., Bonnar, O., Crombag, H. S., & Hall, C. N. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/835728 · Cited by 10
de Oliveira, B. S. A., Milanezi, D. S., Gonzaga, P. D. V., Detoni, F. R., & Soriano, R. N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12172 · Cited by 11
Dyer, A. H., Murphy, C., LAWLOR, B. A., Kennelly, S., StudyGroup, F. T. N., LAWLOR, B. A., Segurado, R., Kennelly, S., Rikkert, M. G. M. O., Howard, R. J., et al. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00800-y · Cited by 11
Self-citationGarcía‐Lluch, G., Peña‐Bautista, C., Moreno, L., Baquero, M., Martínez, A. J. C., & Cháfer‐Pericás, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030924 · Cited by 8
Economic evaluation of the screening for Alzheimer’s disease in China
Ren, Y., Zhou, D., Xing, Q., Gong, F., & Tang, W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.968842 · Cited by 7
“In addition, so far no drug has been identified that can halt the progression of AD (Lawlor et al., 2018; Craft et al., 2020; Koch et al., 2020; Kehoe et al., 2021).”
BackgroundReddin, C., Murphy, R., Hanrahan, C., Loughlin, E. A., Ferguson, J. P., Judge, C. S., Waters, R., Canavan, M. D., Kenny, R. A., & O'Donnell, M. J. (2023) · Age and Ageing · doi:10.1093/ageing/afad044 · Cited by 8
Self-citationBiological Risk Factors Influencing Vascular Cognitive Impairments: A Review of the Evidence
Iluţ, S., Vesa, Ș. C., Văcăraș, V., Brăiță, L., Dăscălescu, V.-C., Fantu, I., & Mureșanu, D.-F. (2023) · Brain Sciences · doi:10.3390/brainsci13071094 · Cited by 9
“Cerebral hypoperfusion [33], endothelial dysfunction, inflammation [34], oxidative stress and neurohormonal activation [35] are some of the known mechanisms involved in cognitive impairment correlated to blood pressure variability [36].”
BackgroundKehoe, P. G., Turner, N. L., Howden, B., Jarutyt, L., Clegg, S., Malone, I. B., Barnes, J., Nielsen, C. F., Sudre, C. H., Wilson, A., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08190 · Cited by 9
White Matter and Alzheimer’s Disease: A Bidirectional Mendelian Randomization Study
Li, Y., Zheng, J., Li, T. X., & Zhang, J. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00353-9 · Cited by 7
“Using MR approaches, our results suggested that white matter damage containing WMH and white matter integrity could not elevate the risk of AD, which was consistent with a previous randomized controlled trial (RCT) showing that hypertension treatment with nilvadipine did not slow the decline in cognition or function i…”
ResultDrug repurposing using meta-analysis of gene expression in Alzheimer’s disease
Jang, H. Y., Oh, J. M., & Kim, I. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.989174 · Cited by 8
“, 2015), and nilvadipine was studied as a treatment in patients with mild to moderate Alzheimer’s disease (Lawlor et al., 2018).”
BackgroundPrevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease
Vu, M., Koponen, M., Taipale, H. T., Tanskanen, A. J., Tiihonen, J., Kettunen, R., Hartikainen, S. A., & Tolppanen, A. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.09.036 · Cited by 8
Kim, S., Kim, K., Nho, K. T., Myung, W., & Won, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200671 · Cited by 7
Mishra, N., Mohan, D., Fuad, S., Basavanagowda, D. M., Alrashid, Z. A., Kaur, A., Rathod, B., Nosher, S., & Heindl, S. E. (2020) · Cureus · doi:10.7759/cureus.12035 · Cited by 10
“The authors also mention that if perhaps cerebral hypoperfusion worsened amyloid deposition, early-stage interventions in AD patients with cerebral blood flow (CBF) altering medications can help prevent dementia in AD patients too [33], which has also been discussed elsewhere [25,41].”
BackgroundMethodInfluentialMartins, G. L., Ferreira, C. N., Palotás, A., Rocha, N. P., & Reis, H. J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327215245 · Cited by 6
“However, in the NILVAD study, a clinical trial that evaluated nilvadipine in patients with mild to moderate AD, no benefits of the drug were observed in this population [94].”
Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimer’s Disease Clinical Trials
Costa, T., Manuello, J., Cauda, F., & Liloia, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220942 · Cited by 6
Dyer, A. H., Murphy, C., LAWLOR, B. A., Kennelly, S., & for the NILVAD Study Group (2021) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5591 · Cited by 8
Self-citationDyer, A. H., Murphy, C., Briggs, R., LAWLOR, B. A., Kennelly, S., & for the NILVAD Study Group (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5377 · Cited by 7
“For details, readers are directed to both the main study protocol(18) and the main results paper.(19) In short, participants were included if they had a diagnosis of Alzheimer Disease as per the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Associat…”
Self-citationClarifying the Relationship Between Benzodiazepines and Dementia
Espinoza, R. T. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.006 · Cited by 6
Genomic analyses reveal new insights into Alzheimer's diseasePreprint
Uffelmann, E., Wightman, D. P., Bahrami, S., Shadrin, A. A., Fominykh, V., Ojima, T., Jiang, C., Benner, C., Moreno, E., Campos, A. I., et al. (2025) · medRxiv · doi:10.1101/2025.10.10.25337470 · Cited by 14
Liu, Y., Chen, S., Li, S., Pei, Z., Fan, S., & Guo, Y. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251362444 · Cited by 10
Bath, P. M., Phan, E. P., Clay, G., Dawson, J., Malhotra, P., Howard, R. J., Pal, S., Wardlaw, J. M., Quinn, T., & Macleod, M. R. (2024) · F1000Research · doi:10.12688/f1000research.157890.1 · Cited by 4
Self-citationMakris, K. C., Konstantinou, C., Perikkou, A., Zdravic, A. B., & Christophi, C. A. (2019) · Environmental Research · doi:10.1016/j.envres.2019.109065 · Cited by 5
Neuroprotection in Alzheimer Disease
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_8 · Cited by 6
Khan, M. S., Rehman, M. T., Altwaijry, N. A., Alafaleq, N. O., Aldobiyan, I., Alokail, M. S., Alzahrani, A. A., Arshad, M., & Alajmi, M. F. (2025) · RSC Advances · doi:10.1039/d5ra04162g · Cited by 4
“12,13 Clinical investigations have demonstrated that Nilvadipine increases hippocampal cerebral blood ow in hypertensive and Alzheimer's patients, indicating improved cerebrovascular regulation.”
Saleh, R. O., Jabir, M. S., Mohammed, J. S., Ahmad, I. S., Ganesan, S., Shankhyan, A., Nanda, A., Ray, S., Zwamel, A. H., & Hussein, A. R. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70405 · Cited by 7
“These combined mechanisms contribute to the reduction of neuronal damage and improved cellular resilience against ER stress [148].”
Li, D., Ao, X., Guan, Y., Qiu, Q., Ren, Y., & Zhang, N. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106921 · Cited by 5
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease
Ballard, C. G., Sultana, J., Doherty, P., Williams, G. H., & Corbett, A. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100329 · Cited by 7
“Subsequent trials of the ARB losartan [22], the calcium channel blocker nilvadipine [23], and the tetracycline antibiotic minocycline [24] were unsuccessful.”
Stone, J., Mitrofanis, J., Johnstone, D. M., & Robinson, S. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231202 · Cited by 4
Cui, T., Yu, P., Feng, X., Song, Q., Yang, D., Li, M., & Feng, L. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01444-2 · Cited by 4
de Heus, R. A. A., de Jong, D. L. K., LAWLOR, B. A., & Claassen, J. A. H. R. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100024 · Cited by 5
“The study found that nilvadipine had no effect on disease progression [19].”
BackgroundSelf-citationTsolaki, M., Tsatali, M. S., Γκιόκα, Μ., Poptsi, E., Tsolaki, A., Papaliagkas, V. T., Tabakis, I.-M., Lazarou, I., Makri, M., Kazis, D. A., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.683131 · Cited by 5
“Future clinical trials of nilvadipine should be restricted to mild and very mild AD patients (100) FP7/2012–2017”
BackgroundSelf-citationWickline, J. L., Smith, S., Shin, R., Odfalk, K., Sanchez, J., Javors, M., Ginsburg, B., & Hopp, S. C. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109454 · Cited by 2
The effect of visit-to-visit blood pressure variability on cognitive function: state-of the-art
Nagai, M., Sible, I. J., Tully, P. J., Po, S. S., & Dasari, T. W. (2025) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2025.100392 · Cited by 7
Treatments for vascular depression in older adults: A systematic review
Flôr-Rodrigues, B., Aissa, S. B., Miranda, D., Compagne, C., Vandel, P., von Gunten, A., Orgeta, V., Mueller, C., Swierkosz-Lenart, K., & Moyano, B. P. (2026) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2026.100249 · Cited by 5
Rajaee, A., Petramfar, P., Ansari, R., Asadi, S., Vazin, A., & Zarshenas, M. M. (2024) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2024.100975 · Cited by 3
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 4
Dyer, A. H., LAWLOR, B. A., Kennelly, S., & for the NILVAD Study Group (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5294 · Cited by 3
Self-citationvan Setten, A., Uleman, J. F., Melis, R. J. F., LAWLOR, B. A., Riksen, N. P., Claassen, J. A. H. R., de Heus, R. A. A., on behalf of NILVAD Study Group, Segurado, R., Kennelly, S., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01294-x · Cited by 6
Self-citationRoberts, J. A., Varma, V. R., Jones, A., & Thambisetty, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240680 · Cited by 8
Eschenhagen, T., & Weil, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_6 · Cited by 3
Amare, F., Mirkazemi, C., Peterson, G. M., & Bezabhe, W. M. M. (2025) · GeroScience · doi:10.1007/s11357-025-01957-3 · Cited by 3
“In most of the included studies, cognitive decline over time was observed in both AHM users and non-users [31, 32, 52, 59, 65, 72], with the exception of one study that reported cognitive improvement in both groups, with greater improvement in the treatment group [63].”
InfluentialSystemic inflammation, delirium and clinical progression in mild-moderate Alzheimer disease
Dyer, A. H., Dolphin, H., Morrison, L., Kenny, T., Fallon, P. G., Cunningham, C. M., O’Connor, A., LAWLOR, B. A., O’Farrelly, C., Bourke, N. M., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106159 · Cited by 4
“40 The current data consist of a secondary analyses of data from the blood and genetic NILVAD sub-study, described in detail below.”
Self-citationShajahan, S., Woodward, M., Anderson, C. S., Carcel, C., Wang, N., Tully, P. J., Peters, R., Harrap, S. B., Poulter, N. R., Mancia, G., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044061 · Cited by 3
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Development
Dash, R., Munni, Y. A., Mitra, S., Dash, N., & Moon, I. S. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_15 · Cited by 5
Protofibrillar Amyloid Beta Modulation of Recombinant hCaV2.2 (N-Type) Voltage-Gated Channels
Kaisis, E., Thei, L., Stephens, G. J., & Dallas, M. L. (2022) · Pharmaceuticals · doi:10.3390/ph15121459 · Cited by 3
“Moreover, a more targeted intervention using nilvadipine, which inhibits both L-type VGCCs and spleen tyrosine kinase activity, failed to demonstrate efficacy in the management of existing dementia in terms of modulating measures of cognition [20].”
BackgroundDrug Discovery from Medicinal Plants against Alzheimer's Disease
Marzouk, M. M., Farid, M. M., Hegazi, N. M., & Ezzat, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch3 · Cited by 4
Cardiovascular Risk Management for All Older Patients?
Mattace-Raso, F. U. S., Goudzwaard, J. A., Polinder‐Bos, H. A., & Tap, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230382 · Cited by 2
Kaloss, A. M., Browning, J. L., Li, J., Pan, Y., Watsen, S., Sontheimer, H. W., Theus, M. H., & Olsen, M. L. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01876-7 · Cited by 1
“In humans, a small clinical trial with anti-hypertension drug Nilvadipine showed improved CBF in the hippocampus [73], however a large phase III trial did not find benefits to Nilvadipine treat-ment in patients with mild to moderate AD [73].”
Alzheimer’s Disease Pharmacotherapy: The Potential for Drug Repurposing
Niha, A., & Loewy, Z. G. (2025) · Neuroscience & Medicine · doi:10.4236/nm.2025.164024 · Cited by 2
Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer’s disease
Khan, S. A., Raza, K., Tiwari, P., El‐Tanani, M., Rabbani, S. A., & Parvez, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1676065 · Cited by 4
Pharmacists a valuable resource for patients with Alzheimer disease and their caregivers
Ryan, M. A. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.09.019 · Cited by 1
Huntington’s Disease and Hypertension: Sorting Out Mixed Messages
Marras, C., Mestre, T., & McDermott, M. (2020) · Movement Disorders · doi:10.1002/mds.28076 · Cited by 1
“Similarly, randomized controlled trials of specific antihypertensive drugs showing theoretical promise as disease-modifying agents have failed to demonstrate an impact on disease progression in Parkinson’s disease and Alzheimer’s disease.(30,31) Also, in HD observational data documenting abnormal lipid metabolism led…”
BackgroundEschenhagen, T., & Weil, J. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_6 · Cited by 2
Psychiatric and Neurological Effects of Cardiovascular Drugs
Govoni, S. M. (2020) · Springer eBooks · doi:10.1007/978-3-319-90305-7_46-1 · Cited by 1
Abdullah, L. I., Crawford, F., Langlois, H., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Hendrix, S. B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/345652 · Cited by 1
Self-citationDyer, A. H., Murphy, C., LAWLOR, B. A., & Kennelly, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.004
Self-citationDivergence in Neuronal Calcium Dysregulation in Brain Aging and Animal Models of AD
Ghoweri, A. O. (2020) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2020.521
Management of Vascular Risk Factors in Dementia
Verdelho, A., & Gonçalves‐Pereira, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-77904-7_8 · Cited by 1
Rosende‐Roca, M., Ruiz, C. A., Esteban, E., Boada, M., Martínková, J., Mellino, S., & Chadha, A. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00017-x
Eschenhagen, T. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_22
Psychiatric and Neurological Effects of Cardiovascular Drugs
Govoni, S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-28008-6_46
Antioxidant and antiinflammatory role of melatonin in Alzheimer's neurodegeneration
Rosales‐Corral, S., Reiter, R. J., & Liu, X. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818698-5.00024-9
Eschenhagen, T. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_24
Eschenhagen, T. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_21
The casual relationship between AD and sleep disorders
Wang, X., & Wu, D. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1147
“The multifaceted character of polygenic Alzheimer's disease (AD) poses considerable therapeutic development hurdles [30].”
BackgroundEschenhagen, T., & Weil, J. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_6
Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936 · Cited by 2
Liu, W., Zhao, Y., Rao, Y., Wu, Z., Peng, Y. F., & Gong, L. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1514054 · Cited by 1
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843888
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843879
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843876
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843867
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843861
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843864
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843870
Ou, Y.-N., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843882
Ou, Y., Yang, Y.-X., Shen, X.-N., Ma, Y.-H., Chen, S.-D., Dong, Q., Tan, L., & Yu, J.-T. (2021) · Figshare · doi:10.6084/m9.figshare.13843885
Eschenhagen, T., & Weil, J. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_6
Direct C(sp 2 )‐H Cyanation of Imidazole N‐Oxides in the Synthesis of Nitrile and Amide Derivatives
Nikiforov, E. A., Гафиятуллина, А. Р., Moseev, T. D., Yaryzhnov, K. A., Вараксин, М. В., Чарушин, В. Н., & Чупахин, О. Н. (2026) · ChemistrySelect · doi:10.1002/slct.73228
Shao, Y., Yin, Y., Cheng, Y., McGeary, J. E., Taveira, T. H., Tsuang, D. W., Logue, M. W., Ayandeh, S., Ahmed, A., ZAMRINI, E. Y., et al. (2026) · Medical Sciences · doi:10.64898/2026.06.02.26354752
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
Rashid, M. I., Abbas, M., TAHIR, R., Alam, T., Noor, A., Ishrat, Z., Mudasir, M., Sarfraz, M. A., Mehboob, U., & Abufatima, I. O. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261461304
Manzine, P. R., Carrasco, M., Fernandes, T. A. A., Alves, S. S., Guzman, L., Driouech, L., Millet, M., Cairasco, N. G., Olloquequi, J., Juan, M. E., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2710112
“…modulation and systemic repur-posed approaches category is important because it addresses non-neuronal mechanisms that may contribute to cognitive decline in AD, including endothelial dysfunction, impaired cerebral blood flow, BBB disruption, neuroinflammation, and vascular risk factors [236–238].”
Mechanisms underlying cerebrovascular dysfunction in driving central nervous system diseases
Lu, J., & Xiao, Y. A. N. G. (2026) · Shengming kexue · doi:10.3724/cbls.2026129
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“Nilvadipine has various bene fi cial properties, including the capacity to improve cerebral blood fl ow, reduce the formation of A b , and exhibit anti-in fl ammatory and anti-tau actions (201, 202).”
BindingDB Entry 50018520: Furazans in Medicinal Chemistry.
BindingDB (2024) · UC San Diego · doi:10.7270/q2280ct9
Alzheimer’s disease genetics converges on microglial and neuronal dysregulation
Uffelmann, E., Wightman, D. P., Bahrami, S., Shadrin, A. A., Fominykh, V., Ojima, T., Jiang, C., Benner, C., Moreno, E., Campos, A. I., et al. (2026) · Nature · doi:10.1038/s41586-026-11206-y
Metadata
- Authors
- Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., Breuilh, L., Daly, L., Hendrix, S., Aisen, P., Gaynor, S., Sheikhi, A., Taekema, D. G., Verhey, F. R., Nemni, R., Nobili, F., Franceschi, M., Frisoni, G., Zanetti, O., Konsta, A., Anastasios, O., Nenopoulou, S., Tsolaki-Tagaraki, F., Pakaski, M., Dereeper, O., de la Sayette, V., Sénéchal, O., Lavenu, I., Devendeville, A., Calais, G., Crawford, F., Mullan, M., & for the NILVAD Study Group
- Affiliations
- Trinity College Dublin (IE)
- University College Dublin (IE)
- King's College London (GB)
- Université de Lille (FR)
- G. Papanikolaou General Hospital (GR)
- Mario Negri Institute for Pharmacological Research (IT)
- University College Cork (IE)
- St. James's Hospital (IE)
- Universität Ulm (DE)
- University of Szeged (HU)
- University of Limerick (IE)
- University of Southern California (US)
- Rijnstate Hospital (NL)
- Maastricht University (NL)
- University of Milan (IT)
- Ospedale Policlinico San Martino (IT)
- MultiMedica (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Aristotle University of Thessaloniki (GR)
- Centre Hospitalier d'Arras (FR)
- Centre Hospitalier de Lens (FR)
- Centre Hospitalier de Béthune (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Groupe Hospitalier de l'Institut Catholique de Lille (FR)
- Roskamp Institute (US)
- Corresponding author
- Lawlor, Brian
- ORCID
- Lawlor, Brian
- Segurado, Ricardo
- Olde Rikkert, Marcel G. M.
- Howard, Robert
- Pasquier, Florence
- Tsolaki, Magda
- Lucca, Ugo
- Molloy, D. William
- Riepe, Matthias W.
- Kálmán, János
- Kenny, Rose Anne
- Walsh, Cathal
- Banzi, Rita
- Daly, Leslie
- Hendrix, Suzanne
- Aisen, Paul
- Sheikhi, Ali
- Verhey, Frans R.
- Nobili, Flavio
- Franceschi, Massimo
- Frisoni, Giovanni
- Zanetti, Orazio
- Konsta, Anastasia
- Nenopoulou, Styliani
- Tsolaki-Tagaraki, Fani
- Lavenu, Isabelle
- Crawford, Fiona
- Mullan, Michael
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-09-24
- Volume
- 15
- Issue
- 9
- Pages
- e1002660
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6152871
- OpenAlex
- W2891955176
- Cited by
- 193
- References
- 29
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 36 · 2020: 49 · 2019: 24 · 2018: 1
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Cork Open Research Archive (University College Cork, Ireland) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc-sa)
- Figshare (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Limerick Institutional Repository (University of Limerick) (submittedVersion, cc-by-nc-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (NF-SI-0616-10042)
- European Commission (279093)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- University College London Hospitals NHS Foundation Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- nilvadipine, Alzheimer's disease, cognitive decline, dihydropyridine calcium channel blockers, disease-modifying therapy, Clinical Dementia Rating, NINCDS-ADRDA criteria, anti-inflammatory activity, amyloid, regional cerebral blood flow, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Male, Middle Aged, Nifedipine, Treatment Outcome, Disease Progression, Nootropic Agents, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.